Bloomage Biotech(SH:688363) Cai Jing Wang·2025-10-29 08:15Core Viewpoint - Huaxi Bio reported a decline in revenue and net profit for the first three quarters of 2025, but showed signs of recovery in the third quarter with improved profitability and operational efficiency [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of approximately 3.163 billion yuan, a year-on-year decrease of 18.36% [1] - The net profit attributable to shareholders was about 252 million yuan, down 30.29% year-on-year [1] - Basic earnings per share were 0.52 yuan, reflecting a decrease of 30.67% compared to the previous year [1] Third Quarter Highlights - In the third quarter of 2025, the company reported revenue of 903 million yuan, a year-on-year decline of 15.16% [1] - The net profit attributable to shareholders for the third quarter was 32 million yuan, showing a significant year-on-year increase of 55.63% [1] - The company has maintained a trend of profit recovery for two consecutive quarters, indicating continuous improvement in operational quality and profitability [1] Management and Strategic Adjustments - Since March 2025, the chairman and general manager have led the management team back to the front lines, focusing on systematic adjustments in business philosophy, direction, and talent organization [1] - The company has achieved a significant improvement in operational quality and efficiency through these strategic changes [1] Cost Management - The sales expense ratio in the third quarter decreased to 34.26%, the lowest level in the past five years, attributed to optimized brand communication and channel structure [1] - The net cash flow from operating activities increased by 859% year-on-year, indicating a strong improvement in core operational metrics [1]